Veristat – a scientific-minded global clinical research organisation (CRO) – have recently announced the expansion of its biometrics capacities by acquiring SQN Clinical, a business in the healthcare arena and one of the largest data focused specialty contract research companies in Europe.
SQN Clinical successfully supports the needs of global pharmaceutical, biotechnology, medical device, and animal health partners with innovative clinical development capabilities including a full spectrum of trial, data, and project management solutions powered by robust statistical analysis and reporting.
The acquisition adds more than 80 employees, increasing Veristat’s European footprint and bolstering one of the company’s most sought after service areas, solidifying its position as a global provider of biometrics solutions.
The evolving complexities of regulations – in the European region in particular – bring about a unique set of challenges that impact how clinical data is managed and governed. SQN Clinical’s team, coupled with Veristat’s end-to-end clinical development and regulatory submission capabilities, provide clients with a trusted resource that can bring the right people, processes and technology together.
Read the full press release here.